ST. LOUIS, Aug. 29 CMS, Inc., an Elekta Company andworldwide leader in radiation treatment planning and workflow managementsolutions, today announced that three sites have delivered clinical treatmentsutilizing Monaco(TM), its next-generation Intensity Modulated Radiotherapy(IMRT) treatment planning system. Allegheny General Hospital in Pittsburgh,Pennsylvania, Erasmus Medical Center in Rotterdam, Netherlands, and FroedtertMemorial Lutheran Hospital in Milwaukee, Wisconsin, have all begun producingtreatment plans with the application.
Featuring biological modeling, constrained optimization, and Monte Carlodose calculation algorithms, Monaco represents a fundamentally new approach toIMRT planning, including a unique and sophisticated set of tools to make theradiotherapy planning process easier, more straightforward and clinicallyreliable.
"The biologically-based Monaco IMRT treatment planning system producesclinically relevant plans, which are dosimetrically superior to plans fromdose-based IMRT treatment planning systems, feature shorter plan deliverytimes, and can be easily verified with normal QA procedures," says MoyedMiften, Ph.D., DABR, and Allegheny General Hospital's Chief of MedicalPhysics. "The multi-criteria optimization and the sensitivity analysis toolsin the Monaco system also help reduce the time needed to optimize IMRT plans."
While IMRT delivers significant improvements for radiation treatment, thetechnology presents challenges, including managing the time and resourceintensive processes associated with planning. With Monaco, CMS offers newapproaches that improve IMRT planning in the following ways:
-- Sensitivity Analysis tool that minimizes trial-and-error by guiding thedecision making process
-- Smart Sequencing(TM), a constrained aperture optimization that producesefficient step-and-shoot segments
-- Biological models, voxel definition controls, and multi-criterial goalsthat provide more intuitive and direct control over the optimization process
Monaco was developed with the University of Tubingen in Germany. MarkusAlber, Ph.D., and colleagues developed the Hyperion project, which is theengine behind the new Monaco system. CMS commercialized these innovativeconcepts and approaches from the Hyperion project to create the foundation forMonaco. The result is an advanced, clinically sophisticated IMRT planningsystem backed by the core research and capabilities of one of the world'sleading research institutions.
CMS, Inc., an Elekta Company, is a worldwide market leader in radiationtreatment planning and workflow management, combining innovative softwareapplications and advanced technology tools to deliver comprehensive treatmentplanning and workflow management solutions that integrate seamlessly in anyclinical environment. With a commitment to product excellence and a reputationfor world-class service and support, CMS makes all members of the treatmentteam more effective in providing patient care.
CMS is part of the Elekta Group, providing oncologists, radiationtherapists, neurosurgeons and many other medical specialists with state of theart tools to fight cancer and brain disorders.
With more than 2,500 employees globally, Elekta's corporate headquartersare located in Stockholm, Sweden and the company is listed on the NordicExchange under the ticker EKTAb. More information can be found atwww.cmsrtp.com and www.elekta.com
SOURCE CMS, Inc.